Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,894 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,867 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07706179 | Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer | not yet recruiting | Phase 2 | 10 | University of Wisconsin, MadisonOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07823907 | Ultrasound-Guided Microwave Ablation for Breast Fibroadenoma: Safety and Cosmetic Outcomes(MWA-FA) | not yet recruiting | N/A | 40 | Al-Azhar UniversityOTHER | 1 | Sep 29, 2026 |
| NCT07847398 | Emergence of Predictive Metabolomic Biomarkers of Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer.(EMMENEO-TN) | not yet recruiting | N/A | 50 | Centre Antoine LacassagneOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07848061 | A Master Regulator of Lipid-Associated Macrophage Function in Cancer(FoMe-LAM) | not yet recruiting | — | 120 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07698106 | Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC | not yet recruiting | Phase 1 / Phase 2 | 60 | University Health Network, TorontoOTHER | 0 | Sep 28, 2026 | clinicaltrials |
| NCT07844018 | ADC Based Therapy Accroding to HER2 Heterogeneous(HER2level) | not yet recruiting | Phase 2 | 88 | Peking University People's HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07844291 | A Prospective, Open-label, Randomized Trial Comparing Switch to A1811 Versus Continued THP Neoadjuvant Therapy After THP Induction in HER2-Positive Breast Cancer(SwithADC) | not yet recruiting | N/A | 432 | Peking University People's HospitalOTHER | 0 | Sep 28, 2026 | clinicaltrials |
| NCT07844759 | SOLIS: Single-Dose Radiotherapy With Omission of Lumpectomy for Intact Small Breast Cancers(SOLIS) | not yet recruiting | N/A | 30 | Renaissance Institute of Precision Oncology and RadiosurgeryOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07419880 | Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer(RECLAIM) | not yet recruiting | Phase 2 | 46 | Fudan UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07840534 | Patient-Initiated Follow-Up for Women After Early Breast Cancer Treatment (LYSA2PIFU)(LYSA2PIFU) | not yet recruiting | N/A | 30 | University College CorkOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07840599 | Fit2ThriveMB: Optimization of a Physical Activity Promotion Intervention for Metastatic Breast Cancer Patients(Fit2ThriveMB) | not yet recruiting | N/A | 224 | Northwestern UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07841704 | NAUTILUS-04: No Axillary Surgical Treatment in Low-Risk Clinically Node-Negative Breast Cancer Without Whole-Breast Radiotherapy - A Prospective, Randomized, Phase III, Non-inferiority Clinical Trial(NAUTILUS-04) | not yet recruiting | N/A | 1,520 | Wonshik HanOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07838649 | Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity | not yet recruiting | Phase 1 | 36 | Washington University School of MedicineOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07185568 | IntraOperative UltraSound Guided vs Wire Guided vs Magnetic Seed Guided Breast-Conserving Surgery for Non-palpable Tumors(MANOLA) | not yet recruiting | N/A | 1,302 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07835698 | The Validation of ICBT Clinical Trial: Disease Stress Adjustment in Breast Cancer Patients(ICBT-TW-2) | not yet recruiting | N/A | 100 | National Health Research Institutes, TaiwanOTHER | 0 | Sep 23, 2026 | clinicaltrials |
| NCT07836257 | A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXd | not yet recruiting | Phase 2 | 28 | Fujian Medical UniversityOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07528768 | HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry. | not yet recruiting | Phase 2 | 750 | The University of The West IndiesOTHER | 3 | Sep 22, 2026 | clinicaltrials |
| NCT07619365 | Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer | not yet recruiting | Phase 2 | 60 | Washington University School of MedicineOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07748377 | Increasing Breast and Colorectal Cancer Screening in the Community | not yet recruiting | N/A | 80 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07770243 | AI-Based Symptom Management for Post-Treatment Breast Cancer Survivors(AIMS-BC) | not yet recruiting | N/A | 36 | Hong Kong Metropolitan UniversityOTHER | 0 | Sep 22, 2026 | clinicaltrials |
| NCT07833085 | CAIX-targeted PET/CT in Solid Tumors(CAIX-PET) | not yet recruiting | N/A | 100 | Zhongnan HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07833891 | Senocohort: Identification of Predictive Biomarkers in Breast Cancer Treatment(SENOCOHORT) | not yet recruiting | — | 500 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Sep 22, 2026 | clinicaltrials |
| NCT07831889 | Hypofractionated Radiotherapy After Breast Reconstruction for Breast Cancer | not yet recruiting | N/A | 960 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT06882499 | Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II(AVATARII) | not yet recruiting | N/A | 74 | Peter MacCallum Cancer Centre, AustraliaOTHER | 0 | Sep 18, 2026 | clinicaltrials |
| NCT07631026 | Wearable Device Tracked Recovery From Autologous Breast Reconstructive Surgery | not yet recruiting | N/A | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07679269 | Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.(EPIK-RO) | not yet recruiting | Phase 2 | 51 | Novartis PharmaceuticalsINDUSTRY | 0 | Sep 18, 2026 | clinicaltrials |
| NCT07828054 | Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab Deruxtecan(MARGARET) | not yet recruiting | Phase 3 | 244 | Mario Negri Institute for Pharmacological ResearchOTHER | 0 | Sep 18, 2026 | clinicaltrials |
| NCT07828652 | Real-world Treatment Outcomes and Safety of Neoadjuvant Pembrolizumab-containing Therapy in Patients With Triple-negative Breast Cancer: Korean Nationwide Multicenter Study (Pembro-Real World) | not yet recruiting | — | 2,000 | Yeon Hee ParkOTHER | 0 | Sep 18, 2026 | clinicaltrials |
| NCT07824869 | A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients | not yet recruiting | Phase 2 | 90 | Shanghai Henlius BiotechINDUSTRY | 0 | Sep 17, 2026 | clinicaltrials |
| NCT07825454 | Pilot Study of Hydroxychloroquine for the Treatment of AIMSS(AIMSS) | not yet recruiting | Phase 2 | 35 | Indiana UniversityOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07826052 | Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast Cancer(ELDER) | not yet recruiting | Phase 2 | 494 | Fudan UniversityOTHER | 0 | Sep 17, 2026 | clinicaltrials |
| NCT07748208 | A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes | not yet recruiting | Phase 2 | 40 | Hoffmann-La RocheINDUSTRY | 0 | Sep 16, 2026 | clinicaltrials |
| NCT07638150 | PRehabilitation Intervention to Modify Eating for Breast Cancer Patients (PRIME)(PRIME) | not yet recruiting | N/A | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07743723 | A Study of IOV-5001 in Adults With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 106 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07819981 | Prehabilitation for Improving Outcomes in Breast Cancer Patients Undergoing Neoadjuvant Systemic Treatment and Surgery | not yet recruiting | N/A | 20 | City of Hope Medical CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07817355 | Dance-Based Exercise for Cancer-Related Fatigue in Breast Cancer Patients(DANCE-BC) | not yet recruiting | N/A | 104 | Comenius UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07651267 | Financial Toxicity, Quality of Life, and Psychological Resources in Breast Cancer Survivors : A Longitudinal Study(FTQoL-BC) | not yet recruiting | — | 160 | Okayama UniversityOTHER | 0 | Sep 11, 2026 | clinicaltrials |
| NCT07814872 | A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment(FATHOM) | not yet recruiting | — | 30,000 | Harvard Medical School (HMS and HSDM)OTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07374796 | Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Breast Cancer | not yet recruiting | — | 450 | University of Maryland, BaltimoreOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07776964 | Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE) | not yet recruiting | N/A | 72 | University of MinnesotaOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811232 | A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers | not yet recruiting | Phase 1 / Phase 2 | 138 | Advenchen Pharmaceuticals, LLC.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07501637 | Mind-Body Group Interventions for Psychological Distress in Young Breast Cancer Survivors | not yet recruiting | N/A | 30 | University of Alabama at BirminghamOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07781800 | Navigation Interventions for Patients With Breast Cancer and High-risk Social Determinants of Health | not yet recruiting | N/A | 180 | Washington University School of MedicineOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07809698 | CT-AI Breast Cancer Opportunistic Screening Health Examination Study | not yet recruiting | N/A | 30,000 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07806084 | Correlation Between ANC and Bone Pain in Breast Cancer Patients Receiving Long-Acting G-CSF(Bone Pain) | not yet recruiting | — | 132 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Sep 8, 2026 | clinicaltrials |
| NCT07807345 | Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic | not yet recruiting | Phase 1 | 285 | Sutro Biopharma, Inc.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07300475 | Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients | not yet recruiting | Phase 1 | 30 | Washington University School of MedicineOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07801898 | Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast Cancer | not yet recruiting | Phase 2 | 36 | The Second Hospital of Anhui Medical UniversityOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07802626 | Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing(MONITOR) | not yet recruiting | Phase 3 | 1,084 | SWOG Cancer Research NetworkNETWORK | 0 | Sep 3, 2026 | clinicaltrials |
| NCT07802847 | Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.(POG) | not yet recruiting | Phase 4 | 794 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 3, 2026 | clinicaltrials |
Data updated 22 hours agoSource updated Sep 29, 2026source: clinicaltrials